Words: Lynne BlundellA global decline in research and development (R&D) funding combined with a pharmaceuticals marketplace that has never been more competitive is changing the conventional relationship between academia and industry.Traditionally, each fed off the other; a reasonably straightforward payment for knowledge. But a new model is emerging that brings the skills of each other together, even at the lab level, to collaboratively problem-solve. Community expectations of medical research are high, and rising, as technology in recent decades has delivered vastly improved treatments and cures. But the science and technology needed to meet these expectations and deliver the next generation of healthcare products and services is now often beyond the resources of any one organisation. It was this implication for future research that in 2009 brought researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) and the University’s Department of Chemical Engineering into a working relationship with technicians from the global pharmaceutical company GlaxoSmithKline (GSK)

Excerpt from: 

ALLIANCE BUILDS R&D CAPACITY